{"pmid":32426292,"pmcid":"PMC7212352","title":"Oral Chemotherapy for Treatment of Lung Cancer.","text":["Oral Chemotherapy for Treatment of Lung Cancer.","The global COVID-19 pandemic has disrupted healthcare delivery, particularly for patients with advanced lung cancer. While certain aspects of care can be safely omitted or delayed, systemic therapy plays an important role in survival and quality of life for patients with advanced lung cancer; limiting access to systemic therapy will compromise cancer-related outcomes. This can be at odds with strategies to mitigate risk of COVID-19 exposure, which include reducing hospital and clinic visits. One important strategy is implementation of oral cancer therapies. Many standard regimens require intravenous infusions but there are specific circumstances where an oral agent could be an acceptable alternative. Integrating oral therapeutics can permit patients to receive effective systemic treatment without the exposure risks associated with frequent infusions. Here, we review currently available oral cytotoxic agents with a potential role in the treatment of lung cancer.","Front Oncol","Jonna, Sushma","Reuss, Joshua E","Kim, Chul","Liu, Stephen V","32426292"],"abstract":["The global COVID-19 pandemic has disrupted healthcare delivery, particularly for patients with advanced lung cancer. While certain aspects of care can be safely omitted or delayed, systemic therapy plays an important role in survival and quality of life for patients with advanced lung cancer; limiting access to systemic therapy will compromise cancer-related outcomes. This can be at odds with strategies to mitigate risk of COVID-19 exposure, which include reducing hospital and clinic visits. One important strategy is implementation of oral cancer therapies. Many standard regimens require intravenous infusions but there are specific circumstances where an oral agent could be an acceptable alternative. Integrating oral therapeutics can permit patients to receive effective systemic treatment without the exposure risks associated with frequent infusions. Here, we review currently available oral cytotoxic agents with a potential role in the treatment of lung cancer."],"journal":"Front Oncol","authors":["Jonna, Sushma","Reuss, Joshua E","Kim, Chul","Liu, Stephen V"],"date":"2020-05-20T11:00:00Z","year":2020,"_id":"32426292","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.3389/fonc.2020.00793","keywords":["capecitabine","chemotherapy","etoposide","oral therapy","temozolomide","topotecan","vinorelbine"],"topics":["Prevention"],"weight":1,"_version_":1667252837948588033,"score":9.490897,"similar":[{"pmid":32416433,"title":"Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience.","text":["Metronomic oral vinorelbine and lung cancer therapy during the COVID 19 pandemic: A single-center experience.","COVID 19 pandemic is a worldwide health emergency. Every single Hospital and Department was forced to radically modify clinical practice decreasing or stopping daily activities. Oncological patients had to carry on treatments in order to prevent disease progression and improve their quality of life. However, many health workers may be a potential source of infection if not tested with swabs but this diagnostic procedure was not suitable universally in Italy. Aiming to reduce hospitalization of our patients with advanced lung cancer, vinorelbine in its metronomic formulation is one of the best strategy. Here, we report the experience with oral vinorelbine in a few patients of our Oncology Department.","Lung Cancer","Rossi, David","32416433"],"abstract":["COVID 19 pandemic is a worldwide health emergency. Every single Hospital and Department was forced to radically modify clinical practice decreasing or stopping daily activities. Oncological patients had to carry on treatments in order to prevent disease progression and improve their quality of life. However, many health workers may be a potential source of infection if not tested with swabs but this diagnostic procedure was not suitable universally in Italy. Aiming to reduce hospitalization of our patients with advanced lung cancer, vinorelbine in its metronomic formulation is one of the best strategy. Here, we report the experience with oral vinorelbine in a few patients of our Oncology Department."],"journal":"Lung Cancer","authors":["Rossi, David"],"date":"2020-05-17T11:00:00Z","year":2020,"_id":"32416433","source":"PubMed","week":"202020|May 11 - May 17","doi":"10.1016/j.lungcan.2020.05.001","keywords":["lung cancer","oral","vinorelbine"],"locations":["Italy","vinorelbine"],"countries":["Italy"],"countries_codes":["ITA|Italy"],"topics":["Prevention"],"weight":1,"_version_":1666994545903009792,"score":322.55676},{"pmid":32360578,"title":"Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic.","text":["Alternative Multidisciplinary Management Options for Locally Advanced Non-Small Cell Lung Cancer During the COVID-19 Global Pandemic.","IMPORTANCE: The COVID-19 pandemic is currently accelerating. Patients with locally advanced non-small cell lung cancer (LA-NSCLC) may require treatment in locations where resources are limited and the prevalence of infection is high. Patients with LA-NSCLC frequently present with comorbidities that increase the risk for severe morbidity and mortality from COVID-19. These risks may be further increased by treatments for LA-NSCLC. OBSERVATION: We present an expert thoracic oncology multidisciplinary (radiation oncology, medical oncology, surgical oncology) consensus opinion of alternative strategies for the treatment of LA-NSCLC during a pandemic, though guiding data is scarce. The overarching goals of these approaches are to reduce the number of visits to a healthcare facility, reduce the risk of SARS-CoV-2 exposure, attenuate the immunocompromising effects of lung cancer therapies, and provide effective oncologic therapy. Patients with resectable disease can be treated with definitive non-operative management if surgical resources are limited or the risks of perioperative care are high. Non-operative options include chemotherapy, chemoimmunotherapy, and radiation therapy with sequential schedules that may or may not affect long-term outcomes in an era in which immunotherapy is available. The order of treatments may be based on patient factors and clinical resources. Whenever radiation therapy is delivered without concurrent chemotherapy, hypofractionated schedules are appropriate. For patients who are confirmed to have COVID-19, usually cancer therapies may be withheld until symptoms have resolved with negative viral test results. CONCLUSIONS AND RELEVANCE: The risk of severe treatment-related morbidity and mortality is significantly elevated for patients undergoing treatment for LA-NSCLC during the COVID-19 pandemic. Adapting alternative treatment strategies as quickly as possible may save lives and should be implemented through communication with the multidisciplinary cancer team.","J Thorac Oncol","Kumar, Sameera","Chmura, Steven","Robinson, Clifford","Lin, Steven H","Gadgeel, Shirish M","Donington, Jessica","Feliciano, Josephine","Stinchcombe, Thomas E","Werner-Wasik, Maria","Edelman, Martin J","Moghanaki, Drew","32360578"],"abstract":["IMPORTANCE: The COVID-19 pandemic is currently accelerating. Patients with locally advanced non-small cell lung cancer (LA-NSCLC) may require treatment in locations where resources are limited and the prevalence of infection is high. Patients with LA-NSCLC frequently present with comorbidities that increase the risk for severe morbidity and mortality from COVID-19. These risks may be further increased by treatments for LA-NSCLC. OBSERVATION: We present an expert thoracic oncology multidisciplinary (radiation oncology, medical oncology, surgical oncology) consensus opinion of alternative strategies for the treatment of LA-NSCLC during a pandemic, though guiding data is scarce. The overarching goals of these approaches are to reduce the number of visits to a healthcare facility, reduce the risk of SARS-CoV-2 exposure, attenuate the immunocompromising effects of lung cancer therapies, and provide effective oncologic therapy. Patients with resectable disease can be treated with definitive non-operative management if surgical resources are limited or the risks of perioperative care are high. Non-operative options include chemotherapy, chemoimmunotherapy, and radiation therapy with sequential schedules that may or may not affect long-term outcomes in an era in which immunotherapy is available. The order of treatments may be based on patient factors and clinical resources. Whenever radiation therapy is delivered without concurrent chemotherapy, hypofractionated schedules are appropriate. For patients who are confirmed to have COVID-19, usually cancer therapies may be withheld until symptoms have resolved with negative viral test results. CONCLUSIONS AND RELEVANCE: The risk of severe treatment-related morbidity and mortality is significantly elevated for patients undergoing treatment for LA-NSCLC during the COVID-19 pandemic. Adapting alternative treatment strategies as quickly as possible may save lives and should be implemented through communication with the multidisciplinary cancer team."],"journal":"J Thorac Oncol","authors":["Kumar, Sameera","Chmura, Steven","Robinson, Clifford","Lin, Steven H","Gadgeel, Shirish M","Donington, Jessica","Feliciano, Josephine","Stinchcombe, Thomas E","Werner-Wasik, Maria","Edelman, Martin J","Moghanaki, Drew"],"date":"2020-05-04T11:00:00Z","year":2020,"_id":"32360578","source":"PubMed","week":"202019|May 04 - May 10","doi":"10.1016/j.jtho.2020.04.016","keywords":["covid","non-small cell lung cancer","sars-cov-2","locally advanced"],"locations":["thoracic"],"topics":["Prevention"],"weight":1,"_version_":1666138495938199552,"score":252.37192},{"pmid":32422364,"title":"Treatment guidance for lung cancer patients during the COVID-19 pandemic.","text":["Treatment guidance for lung cancer patients during the COVID-19 pandemic.","The global COVID-19 pandemic continues to escalate at a rapid pace inundating medical facilities and creating significant challenges globally. The risk of SARS-CoV-2 infection in cancer patients appears to be higher especially as they are more likely to present with an immunocompromised condition, either from the cancer itself or from the treatments they receive. A major consideration in the delivery of cancer care during the pandemic is to balance the risk of patient exposure and infection with the need to provide effective cancer treatment. Many aspects of the SARS-CoV-2 infection remain poorly characterized currently and even less is known about the course of infection in the context of a patient with cancer. As SARS-CoV-2 is highly contagious, the risk of infection directly affects the cancer patient being treated, other cancer patients in close proximity, and health care providers. Infection at any level for patients or providers can cause significant disruption to even the most effective treatment plans. Lung cancer patients, especially those with reduced lung function and cardiopulmonary co-morbidities are more likely to have increased risk and mortality from COVID-19 as one of its common manifestation is as an acute respiratory illness. The purpose of this manuscript is to present a practical multidisciplinary and international overview to assist in treatment for lung cancer patients during this pandemic, with the caveat that evidence is lacking in many areas. It is expected that firmer recommendations can be developed as more evidence becomes available.","J Thorac Oncol","Dingemans, Anne-Marie C","Soo, Ross A","Jazieh, Abdul Rahman","Rice, Shawn J","Kim, Young Tae","Teo, Lynette Ls","Warren, Graham W","Xiao, Shu-Yuan","Smit, Egbert F","Aerts, Joachim G","Yoon, Soon Ho","Veronesi, Giulia","De Cobelli, Francesco","Ramalingam, Suresh S","Garassino, Marina C","Wynes, Murry W","Behera, Madhusmita","Haanen, John","Lu, Shun","Peters, Solange","Ahn, Myung-Ju","Scagliotti, Giorgio V","Adjei, Alex A","Belani, Chandra P","32422364"],"abstract":["The global COVID-19 pandemic continues to escalate at a rapid pace inundating medical facilities and creating significant challenges globally. The risk of SARS-CoV-2 infection in cancer patients appears to be higher especially as they are more likely to present with an immunocompromised condition, either from the cancer itself or from the treatments they receive. A major consideration in the delivery of cancer care during the pandemic is to balance the risk of patient exposure and infection with the need to provide effective cancer treatment. Many aspects of the SARS-CoV-2 infection remain poorly characterized currently and even less is known about the course of infection in the context of a patient with cancer. As SARS-CoV-2 is highly contagious, the risk of infection directly affects the cancer patient being treated, other cancer patients in close proximity, and health care providers. Infection at any level for patients or providers can cause significant disruption to even the most effective treatment plans. Lung cancer patients, especially those with reduced lung function and cardiopulmonary co-morbidities are more likely to have increased risk and mortality from COVID-19 as one of its common manifestation is as an acute respiratory illness. The purpose of this manuscript is to present a practical multidisciplinary and international overview to assist in treatment for lung cancer patients during this pandemic, with the caveat that evidence is lacking in many areas. It is expected that firmer recommendations can be developed as more evidence becomes available."],"journal":"J Thorac Oncol","authors":["Dingemans, Anne-Marie C","Soo, Ross A","Jazieh, Abdul Rahman","Rice, Shawn J","Kim, Young Tae","Teo, Lynette Ls","Warren, Graham W","Xiao, Shu-Yuan","Smit, Egbert F","Aerts, Joachim G","Yoon, Soon Ho","Veronesi, Giulia","De Cobelli, Francesco","Ramalingam, Suresh S","Garassino, Marina C","Wynes, Murry W","Behera, Madhusmita","Haanen, John","Lu, Shun","Peters, Solange","Ahn, Myung-Ju","Scagliotti, Giorgio V","Adjei, Alex A","Belani, Chandra P"],"date":"2020-05-19T11:00:00Z","year":2020,"_id":"32422364","source":"PubMed","week":"202021|May 18 - May 24","doi":"10.1016/j.jtho.2020.05.001","keywords":["covid-19","sars-cov-2","lung cancer","patient care"],"topics":["Prevention"],"weight":1,"_version_":1667254896686006272,"score":240.1673},{"pmid":32329953,"title":"Should we wait or not? The preferable option for patients with stage IV oral cancer in COVID-19 pandemic.","text":["Should we wait or not? The preferable option for patients with stage IV oral cancer in COVID-19 pandemic.","BACKGROUND: The coronavirus infection is rapidly spreading, putting a strain on health care services across the globe. Patients with oral cancer are susceptible often immunosuppressed due to the disease and/or the treatment received. METHODS: We performed a simulation of the currently available data using a multistate and hazards model to provide an objective model for counseling and decision making for health care workers. RESULTS: Stage IV patients with oral cancer who did not receive treatment had progression of disease and an increased mortality rate compared to patients who receive treatment but did not contract COVID-19. The patients who received treatment and got affected with COVID-19 had a far worse impact and higher mortality rate than all other groups. CONCLUSION: Isolation and deferring treatment for stage IV patients with oral cancer, so as to avoid hospital visits and contraction of COVID-19, is an advisable strategy based on this model.","Head Neck","Bhattacharjee, Atanu","Patil, Vijay M","Dikshit, Rajesh","Prabhash, Kumar","Singh, Arjun","Chaturvedi, Pankaj","32329953"],"abstract":["BACKGROUND: The coronavirus infection is rapidly spreading, putting a strain on health care services across the globe. Patients with oral cancer are susceptible often immunosuppressed due to the disease and/or the treatment received. METHODS: We performed a simulation of the currently available data using a multistate and hazards model to provide an objective model for counseling and decision making for health care workers. RESULTS: Stage IV patients with oral cancer who did not receive treatment had progression of disease and an increased mortality rate compared to patients who receive treatment but did not contract COVID-19. The patients who received treatment and got affected with COVID-19 had a far worse impact and higher mortality rate than all other groups. CONCLUSION: Isolation and deferring treatment for stage IV patients with oral cancer, so as to avoid hospital visits and contraction of COVID-19, is an advisable strategy based on this model."],"journal":"Head Neck","authors":["Bhattacharjee, Atanu","Patil, Vijay M","Dikshit, Rajesh","Prabhash, Kumar","Singh, Arjun","Chaturvedi, Pankaj"],"date":"2020-04-25T11:00:00Z","year":2020,"_id":"32329953","source":"PubMed","week":"202017|Apr 20 - Apr 26","doi":"10.1002/hed.26196","keywords":["covid-19","cancer","coronavirus","simulation"],"topics":["Prevention"],"weight":1,"_version_":1666138494683054080,"score":239.66902},{"pmid":32342863,"title":"Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement.","text":["Practice recommendations for lung cancer radiotherapy during the COVID-19 pandemic: An ESTRO-ASTRO consensus statement.","BACKGROUND: The COVID-19 pandemic has caused radiotherapy resource pressures and led to increased risks for lung cancer patients and healthcare staff. An international group of experts in lung cancer radiotherapy established this practice recommendation pertaining to whether and how to adapt radiotherapy for lung cancer in the COVID-19 pandemic. METHODS: For this ESTRO & ASTRO endorsed project, 32 experts in lung cancer radiotherapy contributed to a modified Delphi consensus process. We assessed potential adaptations of radiotherapy in two pandemic scenarios. The first, an early pandemic scenario of risk mitigation, is characterized by an altered risk-benefit ratio of radiotherapy for lung cancer patients due to their increased susceptibility for severe COVID-19 infection, and minimization of patient travelling and exposure of radiotherapy staff. The second, a later pandemic scenario, is characterized by reduced radiotherapy resources requiring patient triage. Six common lung cancer cases were assessed for both scenarios: peripherally located stage I NSCLC, locally advanced NSCLC, postoperative radiotherapy after resection of pN2 NSCLC, thoracic radiotherapy and prophylactic cranial irradiation for limited stage SCLC and palliative thoracic radiotherapy for stage IV NSCLC. RESULTS: In a risk-mitigation pandemic scenario, efforts should be made not to compromise the prognosis of lung cancer patients by departing from guideline-recommended radiotherapy practice. In that same scenario, postponement or interruption of radiotherapy treatment of COVID-19 positive patients is generally recommended to avoid exposure of cancer patients and staff to an increased risk of COVID-19 infection. In a severe pandemic scenario characterized by reduced resources, if patients must be triaged, important factors for triage include potential for cure, relative benefit of radiation, life expectancy, and performance status. Case-specific consensus recommendations regarding multimodality treatment strategies and fractionation of radiotherapy are provided. CONCLUSION: This joint ESTRO-ASTRO practice recommendation established pragmatic and balanced consensus recommendations in common clinical scenarios of radiotherapy for lung cancer in order to address the challenges of the COVID-19 pandemic.","Radiother Oncol","Guckenberger, Matthias","Belka, Claus","Bezjak, Andrea","Bradley, Jeffrey","Daly, Megan E","DeRuysscher, Dirk","Dziadziuszko, Rafal","Faivre-Finn, Corinne","Flentje, Michael","Gore, Elizabeth","Higgins, Kristin A","Iyengar, Puneeth","Kavanagh, Brian D","Kumar, Sameera","Le Pechoux, Cecile","Lievens, Yolande","Lindberg, Karin","McDonald, Fiona","Ramella, Sara","Rengan, Ramesh","Ricardi, Umberto","Rimner, Andreas","Rodrigues, George B","Schild, Steven E","Senan, Suresh","Simone Ii, Charles B","Slotman, Ben J","Stuschke, Martin","Videtic, Greg","Widder, Joachim","Yom, Sue S","Palma, David","32342863"],"abstract":["BACKGROUND: The COVID-19 pandemic has caused radiotherapy resource pressures and led to increased risks for lung cancer patients and healthcare staff. An international group of experts in lung cancer radiotherapy established this practice recommendation pertaining to whether and how to adapt radiotherapy for lung cancer in the COVID-19 pandemic. METHODS: For this ESTRO & ASTRO endorsed project, 32 experts in lung cancer radiotherapy contributed to a modified Delphi consensus process. We assessed potential adaptations of radiotherapy in two pandemic scenarios. The first, an early pandemic scenario of risk mitigation, is characterized by an altered risk-benefit ratio of radiotherapy for lung cancer patients due to their increased susceptibility for severe COVID-19 infection, and minimization of patient travelling and exposure of radiotherapy staff. The second, a later pandemic scenario, is characterized by reduced radiotherapy resources requiring patient triage. Six common lung cancer cases were assessed for both scenarios: peripherally located stage I NSCLC, locally advanced NSCLC, postoperative radiotherapy after resection of pN2 NSCLC, thoracic radiotherapy and prophylactic cranial irradiation for limited stage SCLC and palliative thoracic radiotherapy for stage IV NSCLC. RESULTS: In a risk-mitigation pandemic scenario, efforts should be made not to compromise the prognosis of lung cancer patients by departing from guideline-recommended radiotherapy practice. In that same scenario, postponement or interruption of radiotherapy treatment of COVID-19 positive patients is generally recommended to avoid exposure of cancer patients and staff to an increased risk of COVID-19 infection. In a severe pandemic scenario characterized by reduced resources, if patients must be triaged, important factors for triage include potential for cure, relative benefit of radiation, life expectancy, and performance status. Case-specific consensus recommendations regarding multimodality treatment strategies and fractionation of radiotherapy are provided. CONCLUSION: This joint ESTRO-ASTRO practice recommendation established pragmatic and balanced consensus recommendations in common clinical scenarios of radiotherapy for lung cancer in order to address the challenges of the COVID-19 pandemic."],"journal":"Radiother Oncol","authors":["Guckenberger, Matthias","Belka, Claus","Bezjak, Andrea","Bradley, Jeffrey","Daly, Megan E","DeRuysscher, Dirk","Dziadziuszko, Rafal","Faivre-Finn, Corinne","Flentje, Michael","Gore, Elizabeth","Higgins, Kristin A","Iyengar, Puneeth","Kavanagh, Brian D","Kumar, Sameera","Le Pechoux, Cecile","Lievens, Yolande","Lindberg, Karin","McDonald, Fiona","Ramella, Sara","Rengan, Ramesh","Ricardi, Umberto","Rimner, Andreas","Rodrigues, George B","Schild, Steven E","Senan, Suresh","Simone Ii, Charles B","Slotman, Ben J","Stuschke, Martin","Videtic, Greg","Widder, Joachim","Yom, Sue S","Palma, David"],"date":"2020-04-29T11:00:00Z","year":2020,"_id":"32342863","source":"PubMed","week":"202018|Apr 27 - May 03","doi":"10.1016/j.radonc.2020.04.001","keywords":["covid-19","lung cancer","non-small cell lung cancer","pandemic","radiotherapy","small cell lung cancer"],"locations":["thoracic","thoracic"],"topics":["Prevention"],"weight":1,"_version_":1666138495097241600,"score":237.28029}]}